Title
CHANGE IN PARATHYROID HORMONE AND MORTALITY IN INCIDENT HEMODIALYSIS PATIENTS

Permalink
https://escholarship.org/uc/item/35z450zh

Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION, 30(suppl_3)

ISSN
0931-0509

Authors
Feng, Ming
Streja, Elani
Obi, Yoshitsugu
et al.

Publication Date
2015-05-01

DOI
10.1093/ndt/gfv183.54

License
https://creativecommons.org/licenses/by/4.0/ 4.0

Peer reviewed
Introduction and Aims: Fluctuations in serum intact parathyroid hormone (iPTH) level are commonly observed in maintenance hemodialysis (MHD) patients. However, it is unknown as to whether a rise or decline in serum iPTH has an impact upon survival in this population. We hypothesized that, in patients with elevated baseline iPTH levels, a rise in serum iPTH is associated with an increased mortality risk.

Methods: Among 96,459 incident MHD patients receiving care from a large United States dialysis organization from Jan 2007-Dec 2011, we examined changes in serum iPTH levels measured during their baseline (Q1) and subsequent quarters (Q2), which were defined as unchanged (Δ -50 to +50 pg/mL), decreased (decline greater than 50 pg/mL), and increased iPTH (rise greater than 50 pg/mL). We examined the association between change in iPTH across 4 strata of baseline iPTH (<150, 150-<300, 300-<600 and ≥600 pg/mL) using multivariable Cox models adjusted for case-mix and malnutrition and inflammation complex (MICS) covariates.

Results: The mean±SD age of the study cohort was 63±15 years, among whom 43% were female, 32% were African-American, and 60% were diabetic. In case-mix+MICS adjusted models, an increased iPTH was associated with higher mortality risk among patients with a baseline iPTH ≥300-<600 and ≥600 pg/mL (reference group: unchanged iPTH with baseline iPTH 150-<300 pg/mL).

Conclusions: These findings suggest that a rise in iPTH among patients with baseline levels above the target of 150-<300 pg/mL is associated with higher mortality risk. Further studies are needed to determine if lowering iPTH to the 150-<300 pg/mL range improves outcomes in these patients.